Opinion

Video

ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

Author(s):

Mark A. Socinski, MD,Helena A. Yu, MD

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.

  1. Are there any novel therapies in this treatment space that you find interesting that you would like to discuss that are either new or being presented at ASCO this year?
Related Videos
2 experts are featured in this series.
2 expert is featured in this series.
Related Content
OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Non–Small Cell Lung Cancer | Image Credit: © Katsyarina – stock.adobe.com
December 30th 2024

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 23rd 2024

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

Lung cancer, Image credit: Axel Kock – stock.adobe.com
December 23rd 2024

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC